# US 2012/0251564 A1 · Reovirus compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251564 A1
- Document ID: US20120251564A1
- Status: Published application
- Kind: A1
- Application number: 13/443,797
- Filed: 2012-04-10
- Published: 2012-10-04
- Earliest claimed: 2006-10-25
- Assignees: University of Georgia Research Foundation, Inc.
- Inventors: Holly S. Sellers
- Web page: https://patentgrep.com/patent/US20120251564A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- A61K 2039/525: {Virus}
- C12N 2720/12222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2720/12251: Methods of production or purification of viral material
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to novel strains of avian reovirus isolated from severe cases of Runting Stunting Syndrome in young broiler chickens in southeast United States. The invention is directed to avian reoviruses that impair digestion in poultry, diagnostic assays using nucleotide- or amino acid-specific components of such viruses, and to vaccines that protect chickens from disease caused by such viruses. Nucleotide sequences for the S1 gene, encoding the sigma C minor outer capsid protein, were amplified, and the nucleotide and predicted amino acid sequences were compared with sequences from other recently isolated reovirus field isolates and vaccine strains. Antigenic and molecular characterization of the newly isolated reoviruses revealed a lack of homogeneity with current U.S. isolates, with less than 60% percent amino acid similarity across the sigma C protein. Sequence comparisons with previously reported malabsorption isolates from Europe and Asia revealed a higher amino acid similarity, approaching 80%.

## Claims

### Claim 1

A vaccine comprising antigenic material derived from an avian reovirus, wherein said reovirus comprises an S1 protein, wherein said S1 protein comprises an amino acid sequence set forth in the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, and wherein said antigenic material is selected from the group consisting of live virus, live attenuated virus, inactivated virus, and one or more immunologically active subcomponents, thereof.

### Claim 2 (depends on 1)

The vaccine of claim 1, wherein said reovirus comprises an S1 protein comprising the amino acid sequence set forth in SEQ ID NO: 6.

### Claim 3 (depends on 1)

The vaccine of claim 1 further comprising one or more vaccines selected from the group consisting of infectious bronchitis virus vaccine, Newcastle disease virus vaccine, infectious bursal disease virus vaccine, fowl adenovirus vaccine, EDS virus vaccine, and turkey rhinotracheitis virus vaccine.

### Claim 4

A method of eliciting an immune response in a chicken, the method comprising the step of administering to the chicken an amount of a composition comprising an isolated reovirus effective to elicit an immune response in the chicken, wherein the isolated reovirus comprises an S1 protein, and wherein said S1 protein comprises the amino acid sequence set forth in the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30.

### Claim 5 (depends on 4)

The method of claim 4, wherein the isolated reovirus is designated strain 40973 and has ATCC accession number PTA-7174.

### Claim 6 (depends on 4)

The method of claim 4, wherein the composition further comprises a pharmaceutically acceptable carrier, adjuvant, or diluent.

### Claim 7 (depends on 4)

The method of claim 4, wherein the isolated reovirus is an attenuated live reovirus.

### Claim 8 (depends on 4)

The method of claim 4, wherein the isolated reovirus is an inactivated reovirus.

### Claim 9 (depends on 4)

The method of claim 4, wherein the composition comprises at least 102 titration units of the reovirus.

### Claim 10 (depends on 4)

The method of claim 4, wherein the composition is introduced into the chicken on multiple occasions.

### Claim 11 (depends on 4)

The method of claim 4, wherein the composition is introduced into the chicken during a time period extending from day 1 after hatching to week 18 after hatching.

### Claim 12 (depends on 4)

The method of claim 4, wherein the composition further comprises additional isolated virus particles selected from the group consisting of infectious bronchitis virus, Newcastle disease virus, infectious bursal disease virus, fowl adenovirus, EDS virus, and turkey rhinotracheitis virus.

### Claim 13

A method for measuring the amount of a reovirus in a chicken, the method comprising the steps of:
(a) contacting a chicken sample with an antibody that selectively binds to a reovirus that comprises an S1 protein that comprises an amino acid sequence set forth in the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, and
(b) measuring the amount of binding of the antibody to a component of the chicken sample.

### Claim 14 (depends on 13)

The method of claim 13, wherein an ELISA is used to measure the amount of binding of the antibody to a component of the chicken sample.
